Phaseline

Companies › Rakuten Medical

Rakuten Medical: clinical trials, targets and expected readouts

2 active drug programs in 3 registered trials: 2 Phase 3, 1 Phase 1; Oncology; next expected readout Jun 2027.

Open in Phaseline: competitors, likelihood bands and readouts Company report

Programs

DrugTargetHighest phaseConditionsNext expected readout
ASP-1929 Photoimmunotherapy (PIT)
Anti-EGFR photoimmunotherapy agent
EGFRPhase 3Head and Neck Cancer; Recurrent Head and Neck Squamous Cell CarcinomaJun 2027
Cetuximab Sarotalocan (ASP-1929)
Epidermal growth factor receptor erbB1 binding agent
EGFRPhase 3Recurrent Head and Neck Squamous Cell CarcinomaSep 2028

Trials

Registry idDrugPhaseConditionsAreaExpected readout
NCT03769506ASP-1929 Photoimmunotherapy (PIT)Phase 3Head and Neck CancerOncologyDec 2025
NCT04305795ASP-1929 Photoimmunotherapy (PIT)Phase 1Recurrent Head and Neck Squamous Cell CarcinomaOncologyJun 2027
NCT06699212Cetuximab Sarotalocan (ASP-1929)Phase 3Recurrent Head and Neck Squamous Cell CarcinomaOncologySep 2028

From the company's SEC filings

Private offerings reported to the SEC (Form D)

Targets

EGFR (2)

Companies with the same targets

AstraZeneca Shanghai Henlius Biotech Allist Pharmaceuticals Dizal Pharmaceuticals Betta Pharmaceuticals Jiangsu Hansoh Pharmaceutical Johnson & Johnson (Janssen) Chia Tai Tianqing Pharmaceutical Group Nanjing Shunxin Pharmaceutical Shanghai JMT-Bio Chia Tai Tianqing Pharmaceutical Group

Companies built like this

Wayshine Biopharm Jiangsu Alphamab Biopharmaceuticals ArriVent BioPharma Black Diamond Therapeutics Nanjing Sanhome Pharmaceutical

Pipelines of the same shape: areas, drug types, target families, stage and cash runway.

Programs group the company's trials by drug; the target and mechanism come from Open Targets and ChEMBL via Open Targets; expected readouts are Phaseline's estimate from the registry's primary completion date. Facts from the registries only; the approval likelihood, shown as a band with its track record, is in the app.